Andy Tu

966 total citations
10 papers, 683 citations indexed

About

Andy Tu is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Andy Tu has authored 10 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Andy Tu's work include CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Andy Tu is often cited by papers focused on CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Andy Tu collaborates with scholars based in United States. Andy Tu's co-authors include Xuehua Zhong, Steven E. Jacobsen, Suhua Feng, Hume Stroud, Elena Caro, Hang Gyeong Chin, Jolyon Terragni, Dinshaw J. Patel, Jonathan Hetzel and James A. Wohlschlegel and has published in prestigious journals such as Cell, Blood and Nature Structural & Molecular Biology.

In The Last Decade

Andy Tu

9 papers receiving 675 citations

Peers

Andy Tu

PS

MB

ONCOL

GENET

IMMUN

Nita Amornsiripanitch United States

Wenxia Li China

Ashim Subedee United States

Andrea Voigt Germany

Jiacheng Liu China

Josef Pasulka Czechia

Mikhail Steklov Belgium

Kristin S Krause Germany

Jenna L. Carter United States

Nita Amornsiripanitch United States

Andy Tu

544 ×1.1

PS

306 ×0.9

MB

59 ×0.8

ONCOL

30 ×0.6

GENET

55 ×1.1

IMMUN

Citations per year, relative to Andy Tu Andy Tu (= 1×) peers Nita Amornsiripanitch

Countries citing papers authored by Andy Tu

Since Specialization

Citations

This map shows the geographic impact of Andy Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Tu more than expected).

Fields of papers citing papers by Andy Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Tu. The network helps show where Andy Tu may publish in the future.

Co-authorship network of co-authors of Andy Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Tu. A scholar is included among the top collaborators of Andy Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Tu. Andy Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Scanlon, Elizabeth, Flavian D. Brown, Andy Tu, et al.. (2022). 1332 Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D. Regular and Young Investigator Award Abstracts. A1383–A1383. 1 indexed citations

2.

Tu, Andy, et al.. (2020). Analysis of the Effect of COVID-19 on the Stock Market and Investing Strategies. SSRN Electronic Journal. 39 indexed citations

3.

Bittner‐Eddy, Peter D., et al.. (2017). Discriminating between Interstitial and Circulating Leukocytes in Tissues of the Murine Oral Mucosa Avoiding Nasal-Associated Lymphoid Tissue Contamination. Frontiers in Immunology. 8. 1398–1398. 12 indexed citations

4.

Larson, Sarah M., et al.. (2017). Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy. Human Vaccines & Immunotherapeutics. 13(5). 1094–1104. 24 indexed citations

5.

Gschweng, Eric H., Sarah M. Larson, Andy Tu, et al.. (2014). Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications. Blood. 124(21). 3497–3497. 1 indexed citations

6.

Tyagi, Tulika, Sarah M. Larson, Andy Tu, et al.. (2014). Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies. Blood. 124(21). 655–655. 1 indexed citations

7.

Oliveira, Satiro De, Christine E. Ryan, Francesca Giannoni, et al.. (2013). Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy. Human Gene Therapy. 24(10). 824–839. 51 indexed citations

8.

Larson, Sarah M., et al.. (2013). Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies. Blood. 122(21). 1659–1659. 3 indexed citations

9.

Zhong, Xuehua, Christopher J. Hale, Julie A. Law, et al.. (2012). DDR complex facilitates global association of RNA polymerase V to promoters and evolutionarily young transposons. Nature Structural & Molecular Biology. 19(9). 870–875. 163 indexed citations

10.

Du, Jiamu, Xuehua Zhong, Yana V. Bernatavichute, et al.. (2012). Dual Binding of Chromomethylase Domains to H3K9me2-Containing Nucleosomes Directs DNA Methylation in Plants. Cell. 151(1). 167–180. 388 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact